Małgorzata Stachowicz

Medical University of Silesia in Katowice, Katowice, Silesian Voivodeship, Poland

Are you Małgorzata Stachowicz?

Claim your profile

Publications (13)19.65 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Eating disorders constitute a dynamically developing group of diseases, in which only some have well-established diagnostic criteria, e.g. anorexia nervosa or bulimia nervosa. Many symptoms of eating disorders are hard to be qualified to any known disorder from that group, and quantity and diversity of symptoms connected to eating grow systematically. It makes the work of clinicians and psychotherapists more difficult, as well as hampers communication between specialists. It is also a challenge for scientists to create new qualifications based on known and theoretical pathomechanisms connected to disruptions in food intake regulation.
    Psychiatria polska 09/2013; 47(5):897-907. · 1.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of the study: There are different factors which have an impact on the course of schizophrenia. Among those, a lifetime history of substance use disorder is associated with worse clinical functioning of patients suffering from schizophrenia. Psychoactive substances exert a negative impact on cognitive functions, there- fore their use in schizophrenia could further deteriorate cognition in these patients. However, studies evaluating the influence of the substance use on cognitive functioning in schizophrenia patients have greatly differed in methodology, research strategies, and the focus on abused substances. Therefore, the comparison of cognitive functions between schizophrenia patients with or without concomitant substance abuse brought about highly heterogenous results. The aim of the study is an assessment of cognitive func- tioning in abstinent schizophrenia patients with various previous pattern of psychoactive substance abuse. Methods used: The study was performed on a group of 80 schizophrenia patients (74 male, 6 female), aged 18−40 (mean 25) years, of whom in 40, a co-morbid psychoactive substance abuse was diagnosed. The latter group was subdivided, based on their predominant type of substance (opioid, amphetamine, or cannabis). All patients were examined during clinical im- provement, and patients with comorbid substance abuse, after a six-week period of detoxification in a therapeutic community. A battery of neuropsychiatric tests was used, which included subtests of Trail Making Test, Stroop test and Verbal Fluency Test. Results: No significant differences in clinical factors and cog- nitive functioning between two examined groups were found. However, when the patients were divided according to their pattern of substance addiction, it turned out that the group of patients with cannabis, despite the shortest duration of disease and that of addiction, and highest percentage of using atypical antipsychotics, performed worse on all cognitive tests, significantly so on Stroop’s and Fluency tests, compared to the groups with predominant opioid or amphetamine abuse. Statistically significant effect for the Stroop RCNb test was found when comparing three group with ANOVA (p < 0.05) as well as in individual comparisons between cannabis and opiates group (p = 0.03) and between cannabis and stimulants group (p < 0.05). Statistically significant effect for the Stroop NCWd test was obtained in the comparison of three group with ANOVA (p = 0.018) and in individual comparisons between cannabis and opiates group (p = 0.009) and between cannabis and stimulants group (p = 0.02). Statistically significant effect for the Phonological fluency test was obtained in the comparison of three group with ANOVA (p < 0.05) and in individual comparison between cannabis and amphetamine group (p = 0.013). Finally, significant individual difference in the Categorical fluency test was obtained between cannabis and opiates group (p < 0.05). Conclusions: Abstinent schizophrenic patients who previously abused cannabis have worse cognitive functioning compared to other schizophrenic patients with comorbid substance abuse. A possible role of previous cannabis use or cannabis withdrawal in this phenomenon is discussed. We believe that the results of our study may add to the ongoing controversy concerning the effect of cannabis on cognitive functions in schizophrenia. References [1] Krysta, K., 2007. Impact of neuroleptic treatment on cognitive functions in schizophrenia with comorbid addiction to substances. Eur. Neuropsy- chopharmacol. 17(Suppl. 4), S435. [2] Krysta, K., Krupka-Matuszczyk, I., Janas-Kozik, M., Stachowicz M., 2011. Comorbidity of a serious mental illness with an addiction to psychoactive substances, in: Uehara, T. (Ed.), Psychiatric disorders − trends and developments. InTech., Rijeka, pp. 430–442. [3] Potvin, S., Joyal, C.C., Pelletier, J, Stip, E., 2008. Contradictory cogni- tive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res. 100, 242–251.
    25th ECNP Congress; 10/2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A substantial proportion of patients with schizophrenia have co-morbid psychoactive substance use, which can influence their cognitive functions. The aim of this study was to assess cognitive functioning in abstinent schizophrenia patients with various previous patterns of psychoactive substance use. The study was performed on a group of 80 schizophrenia patients (74 men, 6 women), aged 18-40 (mean 25) years, of whom in 40 a co-morbid psychoactive substance abuse was diagnosed. The latter group was subdivided, based on their predominant type of substance (opioid, amphetamine, or cannabis). All patients were examined during clinical improvement, and patients with comorbid substance use were also examined after a 6-week period of detoxification in a therapeutic community. A battery of neuropsychiatric tests was used, which included subtests of Trail Making test, Stroop test and Verbal Fluency test. No significant differences in clinical factors and cognitive functioning between the 2 examined groups were found. However, when the patients were divided according to their pattern of substance use, it turned out that the group of patients who used cannabis, despite the shortest duration of disease and that of addiction, and highest percentage of using atypical antipsychotics, performed worse on all cognitive tests, significantly so on Stroop and Fluency tests, compared to the groups with predominant opioid or amphetamine use. Abstinent schizophrenic patients who previously used cannabis have worse cognitive functioning compared to other schizophrenic patients with comorbid substance use. The possible role of previous cannabis use or cannabis withdrawal in this phenomenon is discussed.
    Medical science monitor: international medical journal of experimental and clinical research 08/2012; 18(9):CR581-6. · 1.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to analyze the pattern of leptin and orexin A plasma levels in patients with the restrictive type of anorexia nervosa (AN-R), during the course of treatment. Thirty females with AN-R, aged 18.0 ± 1.6 years (mean ± SD), range of 15.5-21.0 years, were investigated before and after 2, 3, and 6 months of treatment, which included a normocaloric diet and cognitive-behavioral psychotherapy. The control group consisted of 20 age-matched, healthy control females. Before the therapy, both leptin and orexin A plasma levels were significantly lower than in the control group and were negatively correlated. During treatment, leptin levels increased and, after 6 months, showed a correlation with body mass index (BMI). Orexin A levels showed a further decrease during treatment, with no correlation with BMI. The results corroborate those of other researchers showing a decrease of leptin levels in patients with AN-R and its increase with body mass increment. They may also suggest a possible relationship between leptin and orexin A plasma level patterns in such patients.
    Regulatory Peptides 02/2011; 168(1-3):5-9. · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: rpose of the study:Current research on anorexia nervosa (AN) concentrates on the role of neuropeptides in AN development as well as on the importance of genetic factors. The DSM-IV classification treats AN as a single disorder with two main clinical pictures (restrictive type − AN-R, and binge–purging type − AN-BP). Orexin A (OXA) is a neuropeptide that plays a role in arousal and in the regulation of energy balances. Ghrelin (GRE) is a peptide exhibiting strong orexigenic, adipogenic and somatotropic properties. The aim of the present study was to analyse OXA plasma levels and total GRE plasma levels in girls with AN-BP during cognitivebehavioural treatment (CBT). Methods used: A group of 12 girls with AN-BP (according to DSM-IV, ICD-10 criteria) was studied before and after 2, 3 and 6 months of treatment including normocaloric diet CBT. A group of 20 healthy girls with a mean BMI of 21.4 kg/m2 (SEM = 0.460) served as controls. Plasma levels were determined by radioimmunoassay (RIA, Linco Research, Inc.) using LKB Wallac Clini Gamma 1272 gamma counter.Summary of results: The average age of onset of AN was 17.63 years (SEM = 0.523) and average age at admission was 18.75 years (SEM = 0.572). The average duration of disease was 12.83 months (SEM = 0, 1,445). The AN-BP and control groups were age-matched (Mann–Whitney U test, p = 0.9534). We observed a statistically significant increase of BMI in AN-BP patients, but still BMI was statistically significantly lower in patients than in controls (patients’ BMI at admission: 15.83 kg/m2 , SEM = 0.441 p<0.001; at 2 months: 16.38 kg/m2 , SEM = 0.528 p<0.001; at 3 months: 18.00 kg/m2 , SEM = 0.567 p<0.001; at 6 months: 18.56 kg/m2 , SEM = 0.627 p = 0.0031). The AN-BP and control groups had statistically significantly different serum OXA levels, the serum OXA level of patients being lower than that of controls at every assessment (p = 0.0127 at admission, p = 0.0240 after two months of treatment, and p<0.001after three and six months of treatment, Mann–Whitney U test). The AN-BP and control groups had similar serum GRE levels at every assessment (p = 0.2429, 0.3918, 0.1611, 0.0617, at admission, 2, 3, and 6 months, respectively). We observed a statistically significant negative correlation between BMI and serum OXA in AN-BP patients at every assessment during the six months of observation; the higher the value of BMI, the lower the serum OXA level (R = −0.3315; p = 0.0214, Spearman correlation). There was no statistically significant correlation between BMI and OXA in the control group (p = 0.1707, Spearman correlation). No statistically significant correlation between BMI and serum GRE levels in controls or in AN-BP patients was found at any assessment during the six months of observation (p = 0.1230 and R = −0.1054; p = 0.4758, respectively; Spearman correlation). There was a statistically significant positive correlation between OXA and GRE levels in AN-BP patients (R = 0.5165, p<0.001); when serum OXA level increased, serum GRE level increased too. Conclusions: Analysis of the roles of OXA and GRE in AN-BP patients shows that only OXA plays a role in AN-BP.
    European Neuropsychopharmacology - EUR NEUROPSYCHOPHARMACOL. 01/2011; 21.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Light therapy refers to two different categories of treatment. One of them is used in common medical practice and the other in complementary medicine. The aim of the study was to assess the effect of short time (6 weeks) bright light treatment (BLT) on depressive symptoms in female patients with the restrictive type of anorexia nervosa (AN-R). Twenty-four girls, aged 15-20 (mean 17.4±1) years, diagnosed as AN-R, with concomitant depressive symptoms ≥17 points on the 21-item Hamilton Depression Rating Scale (HDRS) were studied. All girls received cognitive behavioral therapy. Among them, twelve were randomly assigned to additional treatment with BLT for 6 weeks (10,000 lux, 30 min daily). Both groups did not differ on baseline demographic and clinical parameters. The assessments of depression by means of HDRS and measuring of body mass index (BMI) were done weekly throughout the treatment. Improvement of depression was significantly greater in the group receiving BLT, with a significant difference between groups in depression intensity after 5 and 6 weeks. There was no difference in the increase of BMI between groups after 6 weeks, although such increase started earlier in patients treated with BLT. Six weeks of treatment may be an insufficient duration to draw the conclusion about the efficacy of BLT and a follow-up is needed to assess the maintenance of the effect. The results obtained may suggest that BLT could be an effective non-pharmacological modality for the treatment of depression in patients with AN-R.
    Journal of affective disorders 11/2010; 130(3):462-5. · 3.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to examine serum concentration of leptin and that of the soluble form, the Ob-Re receptor, in patients with colorectal cancer, as well as to examine the level of leptin mRNA and that of its receptors, Ob-Ra and Ob-Rb, in large intestine specimens collected from patients with colorectal cancer, depending on cancer clinical and pathological progression and BMI. A total of 146 patients with colorectal cancer in a I-IV stage scale according to the TNM Classification were enrolled. The patients were divided into two groups according to BMI calculations based on body weight and height: a Study group (BMI greater than or equal to 25 kg/m2) of 75 patients aged 57 plus or minus 4.5 years and a Control group (20 less than BMI less than 25 kg/m2) of 71 patients aged 60 plus or minus 5 years. The experimental part of the work was performed in two stages: Stage I regarding the assay of leptin concentration and that of its soluble receptor, Ob-Re, in the serum of patients with the use of the ELISA method; and Stage II to determine the number of leptin mRNA copies and two isoforms of leptin receptors, Ob-Ra and Ob-Rb, using the QRT-PCR method in tissue specimens collected from 146 patients. In our results the concentration of serum leptin and Ob-Re was not dependent on the stage of clinical and pathological progression of the cancer. There was a statistically significant higher serum leptin level in colon cancer patients who were overweight or obese compared to patients with normal weight. No presence of mRNA of the gene encoding leptin was found in tissues collected from colorectal cancer patients. The number of mRNA copies of Ob-Rb was statistically significantly higher in all the study groups compared to the reference tissues.
    Journal of biological regulators and homeostatic agents 01/2010; 24(3):287-95. · 5.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pathogenesis of AnorexiaNervosa (AN) is still not entirely understood. DSM-IV classification differentiates two AN types: the restricting type (AN-R) and the binge-eating/purging type (AN-BP). We investigated four young women suffered from AN (two with AN-R and two with AN-BP) and the other four were our control group who did not suffer from eating disorder. The oligonucleotide microarray method (HG-U133A, Affymetrix) was used to determine the expression profile of genes coding fat tissue protein. On the oligonucleotide microarray HG-U133A were analyzed 15 transcripts representing 9 fat tissue genes (leptin, resistin, tumor necrosis factor, adiponectin, angiotensinogen, interleukin 6, chemerin, visvatin and SERPINE 1), which are potentially involved in mechanism of food intake and energy balance. The total RNA was extracted from peripheral blood mononuclears. The oligonucleotide microarray method analyzes genes expression by using the phenomenon of hybridization of single-thread RNA fragments with complementary DNA probes. The results were normalized using RMAExpress. The U Mann-Whitney test was used for statistical analysis. The p < 0.05 was accepted as the essential level of statistical significance. Statistical analysis was measured by using Statistica version 7.1 PL. None of 15 transcripts coding fat tissue protein differentiate two type of AN: the restrictive type of AN and binge-eating type of AN (p=0.7901) and none of investigated transcripts differentiate either the restrictive type of AN and control group (p=0.7001) or bingeeating type of AN and control group (p=0.8641). The fat tissue protein did not seem to be responsible for food intake.
    European Psychiatry - EUR PSYCHIAT. 01/2009; 24.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: tion: Anorexia nervosa (AN) is a disease of complex pathogenesis. Anorexia nervosa (AN) is an eating disorder most common among adolescent girls and young women. The incidence of AN is estimated at 0.5-1% among adolescent girls and up to 0.8% among young women. AN mortality rate reaches 15 %. Main AN symptoms include a body mass loss and a constant fear ofweight gain. DSM-IV classification differentiates two AN types: the restricting type (AN-R) and the binge-eating/purging type (AN-BP). The AN-R type is characterized by using a radical diet limiting the quantity and quality ofeaten food. AN-Rpatients do not use laxatives, dehydrants or anacathartics to "clean" theirbodies. However, AN-BP patients - apart from being on a dietalso try to "clean" their bodies by means oflaxatives, dehydrants or anacathartics. A lot of observations suggest a very complex system in charge ofregulating energy balance and body weight. Itis thought, the hypothalamus is the key to control offood intake. There are two important places: lateral hypothalamus which playa role as a hunger center and ventromedial hypothalamus which play a role as a satiety center. The results ofsome molecular-genetic studies may suggest that these two types of AN can be separate disorders. Several genes have been isolated that encode proteins that affect food intake, energy metabolism and body weight. It is very difficult to understand their role in the control of body weight in Anorexia Nervosa. Material and Methods: We investigated four young women suffered from AN (two with AN-R and two with AN-BP) and the other four were our control group who did not suffer from eating disorder. The oligonucleotide microarray method (HGU133A, Affymetrix) was used to determine the expression profile of genes coding orexigenic peptides, anorexigenic peptides and fat tissue protein. On the oligonucleotide microarray HG-U133A were analyzed 65 transcripts which are potentially involved in mechanism of food intake and energy balance. The total RNA was extracted from peripheral blood mononuclears. The oligonucleotide microarray method analyzes genes expression by using the phenomenon ofhybridization ofsingle-threadRNA fragments with complementary DNA probes. Aim: Our aim was to investigate panel ofselected genes connecting with food intake in AN patients and searching molecular markers in Anorexia Nervosa. Results: The results were normalized using RMAExpress. The patients' transcriptomes were compared using cluster analysis. Differentiating genes were determined using Bland-Altman graph analysis. Cluster analysis demonstrated that the profile of gene expression in AN patients and control group was similar and do not differentiate AN-R and AN-BP patients and AN patients and control group. The Bland Altman analysis did not show differentiate genes between compared groups. Conclusion: Our results suggest that this panel genes involving in regulation offood intake do not seem to be a potential molecular marker in Anorexia Nervosa. The molecular researchers will be make with personality features.
    European Neuropsychopharmacology - EUR NEUROPSYCHOPHARMACOL. 01/2009; 19.
  • Cytokine 01/2009; 48(1):53-53. · 2.52 Impact Factor
  • European Psychiatry - EUR PSYCHIAT. 01/2008; 23.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anorexia nervosa is a serious eating disorder with the highest mortality rate of any psychiatric disorder. The DSM-IV classification differentiates two AN types: the restricting type (AN-R) and the binge-eating/purging type (AN-BP). Leptin (LEP) levels can be thought of as a signal to the body of its energy reserves. The leptin receptor (including all its mRNA isoforms) is expressed in many tissues. Our aim was to discover the transcript expression profile of the LEP receptor-coding gene in the peripheral blood mononuclears in AN-R and AN-BP patients. Three young women suffering from Anorexia nervosa (one with AN-BP and two with AN-R) took part in the study, along with three non-anorexic subjects as our reference group. LEP receptor gene expression was examined using the oligonucleotide microarray method (HG-U133A, Affymetrix). The results were normalized using RMAExpress. Next, the accumulation analysis method was used (clustering). Hierarchical clustering resulted in three groups of separate clusters. The first group (cluster I) consisted of AN-R patients. The next group (cluster II) consisted of reference group patients suffering from different psychic disorders not related to eating disorders. Cluster III consisted of two patients--the first with AN-BP and the second with an adaptive disorder.
    Cellular & Molecular Biology Letters 02/2006; 11(1):62-9. · 1.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to discover the transcript expression profile of selected genes coding receptors of leptin and orexin A and B by using the oligonucleotide microarray technique (Affymetrix, HG-U133A) in patients who suffered from anorexia nervosa (AN). The peripheral blood of mononuclear cells (PBMC) of four AN patients complying with the ICD-10 and the AN diagnostic criteria DSM IV were analysed. Two patients suffered from the restricting type of AN (AN-R) and two suffered from the binge-eating/ purging type of AN (AN-BP). Four patients were our reference group and they did not suffer from eating disorders. The material used in the assay was the total RNA which was isolated from the PBMC of patients. The total RNA was used to investigate the transcript expression profile of selected genes by using the oligonucleotide microarray technique (Affymetrix, HG-U133A). For six and for eight oligonucleotide microarrays, the accumulation analysis method was used (clustering, Cluster v 3.0) to analyse the results. Hierarchical clustering resulted in separate clusters for patients who suffered from AN-R, AN-BP and patients from the reference group. Taking into consideration the hierarchical clustering for six and for eight oligonucleotide microarray performing different transcript expression profile of selected genes coding orexigenic peptides (OXA and OXB) and anorexigenic peptides (LEP) we suggest that the oligonucleotide microarray method differentiates two type of anorexia nervosa: the restricting type of AN (AN-R) and the binge-eating/purging type (AN-BP).
    Psychiatria polska 41(3):377-86. · 1.48 Impact Factor